FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The authors note that in addition, there was an improvement in sexual function, which is promising for the potential future for this drug. The authors evaluated the endometrial stripe with MRI; obtaining these images, they were able to delineate pelvic floor anatomy better. Post treatment MRI demonstrated results in support of this drug as well. The authors advocate that enobosarm is a safe and tolerable drug. This is the first study to assess role of a SARM for SUI. ASTRID (Assessing Enobosarm for Stress Urinary Incontinence Disorder), a Phase 2 placebo controlled clinical trial to further investigate safety and efficacy is ongoing now.
Study funded by GTx
Presented by: Kenneth M. Peters, MD¹
Co-Authors: Diane Newman DNP², Laurence Belkoff DO³, Kiran Nandalur MD¹, Mary Ann Johnston PharmD⁴, Susan Small RPh⁴, Ryan Taylor PhD⁴ and Larry Sirls MD¹
1. Professor and Chairman of Urology Oakland University William Beaumont School of Medicine, Rochester, MI
2. University of Pennsylvania, Philadelphia, PA
3. Urological Consultants of SEPA, Bala Cynwyd, PA
4. GTx, Inc.,Memphis, TN
Written by: Cristina Palmer, DO. Female Urology, Pelvic Reconstruction, Voiding Dysfunction Fellow, Department of Urology, UC Irvine Medical Center, Orange, California at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Winter Meeting (SUFU 2018), February 27-March 3, 2018, Austin, Texas